SEC Form 4 · accession 0000899243-19-001869
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Oxtoby
Officer — Chief Commercial Officer
Period of report
Jan 22, 2019
Accepted (ET)
Jan 24, 2019 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Jan 22, 2019 | A | 12,000 | $0.00 | A | 12,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $21.94 | Jan 22, 2019 | A | 150,000 | A | — | Jan 22, 2029 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- F2The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 22, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.